Today’s Research Reports on Resverlogix, Aphria, IMV and Oncolytics Biotech

NEW YORK, NY / ACCESSWIRE / June 5, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI has Initiated Coverage Today on:

Resverlogix Corp.
https://rdinvesting.com/news/?ticker=RVX.TO

Aphria Inc.
https://rdinvesting.com/news/?ticker=APH.TO

IMV Inc.
https://rdinvesting.com/news/?ticker=IMV.TO

Oncolytics Biotech Inc.
https://rdinvesting.com/news/?ticker=ONC.TO

Resverlogix’s stock jumped 6.20% Monday, to close the day at $1.37. The stock recorded a trading volume of 127,925 shares, which was above its three months average volume of 86,736 shares. In the last year, Resverlogix’s shares have traded in a range of 1.11 – 2.47. The share price has gained 23.42% from its 52 week low. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $1.37 is below its 200-day moving average of $1.68. Shares of Resverlogix have fallen approximately 33.17 percent year-to-date.

Access RDI’s Resverlogix Corp. Research Report at:
https://rdinvesting.com/news/?ticker=RVX.TO

On Monday, shares of Aphria recorded a trading volume of 3,919,016 shares, which was below the three months average volume of 4,267,770 shares. The stock ended the day 2.12% higher at 12.03. The share price has gained 164.40% from its 52-week low with a 52-week trading range of 4.55 – 24.75. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $11.17 is below its 200-day moving average of $13.91. Shares of Aphria are trading at a Price to Earnings ratio of 58.40. Shares of Aphria have fallen approximately 35.67 percent year-to-date.

Access RDI’s Aphria Inc. Research Report at:
https://rdinvesting.com/news/?ticker=APH.TO

IMV’s stock moved 5.60% lower Monday, to close the day at $8.26. The stock recorded a trading volume of 121,920 shares, which was above its three months average volume of 80,788 shares. In the last year, IMV’s shares have traded in a range of 3.33 – 9.49. The share price has gained 148.05% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $7.18 is greater than its 200-day moving average of $6.59. Shares of IMV have gained approximately 9.69 percent year-to-date.

Access RDI’s IMV Inc. Research Report at:
https://rdinvesting.com/news/?ticker=IMV.TO

On Monday, shares of Oncolytics Biotech recorded a trading volume of 21,539 shares, which was below the three months average volume of 188,568 shares. The stock ended the day 0.98% lower at 8.07. The share price has gained 101.75% from its 52-week low with a 52-week trading range of 4.00 – 10.67. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $7.58 is greater than its 200-day moving average of $7.21. Shares of Oncolytics Biotech have gained approximately 19.38 percent year-to-date.

Access RDI’s Oncolytics Biotech Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ONC.TO

Our Actionable Research on Resverlogix Corp. (TSX: RVX.TO), Aphria Inc. (TSX: APH.TO), IMV Inc. (TSX: IMV.TO) and Oncolytics Biotech Inc. (TSX: ONC.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 501771